|
Optimizing the Primary Recovery Step in Nonaffinity Purification Schemes for HuMAbs
|
|
|
| By
Jue (Michelle) Wang, PhD
,
Timothy Diehl
,
Mark Watkins-Fischl
,
Deborah Perkins
,
Deena Aguiar
,
Alahari Arunakumari, PhD
|
|
|
|
An alternative approach to traditional Protein A schemes is comparable in overall efficiency, product recovery, and quality.
|
|
|
|
Solutions for Purification of Fc-fusion Proteins
|
|
|
| By
Douglas W. Rea
,
Michiel E. Ultee, PhD
,
Sharon X. Chen
,
Thomas P. Loisel
|
|
|
|
When platform processes are applied to fusion molecules, innovation and flexibility are needed.
|
|
|
|
Process-Scale Precipitation of Impurities in Mammalian Cell Culture Broth
|
|
|
| By
Judy Glynn
|
|
|
|
If certain engineering challenges can be addressed, precipitation may prove to be a valuable tool for antibody purification.
|
|
|
|
Purification of IgM Monoclonal Antibodies
|
|
|
| By
Pete Gagnon
,
Frank Hensel
,
Richard Richieri
|
|
|
|
Manufacturing challenges surround the use of IgM monoclonal antibodies, but these can be overcome with current technology.
|
|
|
|
Economic Drivers and Trade-Offs in Antibody Purification Processes
|
|
|
| By
Suzanne S. Farid, PhD
|
|
|
|
The future of therapeutic MAbs lies in the development of economically feasible downstream processes.
|
|
|
